Cover Image
市場調查報告書

抗體藥物複合體 (ADC:Antibody Drug Conjugate) 市場

Antibody Drug Conjugates Market (4th Edition), 2017-2030

出版商 ROOTS ANALYSIS 商品編碼 283285
出版日期 內容資訊 英文 556 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
抗體藥物複合體 (ADC:Antibody Drug Conjugate) 市場 Antibody Drug Conjugates Market (4th Edition), 2017-2030
出版日期: 2017年11月15日 內容資訊: 英文 556 Pages
簡介

本報告提供抗體藥物複合體 (ADC)的市場調查,癌症治療的ADC概要、優點,臨床及前臨床開發平台趨勢,ADC主要適應病症症,主要企業的簡介及產品平台趨勢,企業間的聯盟、合作等狀況,風險企業投資、學術津貼等趨勢,專利趨勢,主要藥物的對象患者人口及銷售額的預測,SWOT分析,專家採訪,未來展望等彙整資料。

第1章 序章

第2章 摘要整理

第3章 簡介

  • 概要
  • 癌症治療的演進
  • 癌症的治療方法
    • 外科手術
    • 放射治療
    • 化療
    • 標靶治療
  • 癌症治療的單株抗體
  • ADC:重要組成部分
    • 抗體
    • 細胞毒素
    • 連接試劑
  • 超越傳統治療方法的ADC的優點
  • ADC、單株抗體、低分子醫藥品:主要特性比較
  • ADC的ADME特性

第4章 市場概要

  • 概要
  • 臨床實驗平台
  • 前臨床開發平台

第5章 KOL

  • 背景
  • 目前研究環境
  • 著名的KOL

第6章 ADC的主要治療部門

  • 概要
  • 骨髓惡性腫瘤
    • 白血病、淋巴瘤
    • 多發性骨髓瘤
  • 固態癌症
    • 轉移性黑色素瘤
    • 肺癌
    • 膀胱癌
    • 腎臟癌
    • COPD (慢性阻塞性肺病)
    • 乳癌
    • 神經膠質母細胞瘤
    • 直腸癌
    • 前列腺癌

第7章 企業及藥物簡介

  • 概要
  • AbbVie
  • Astellas Pharma Inc.
  • Bayer HealthCare
  • Biotest Pharmaceuticals
  • Celldex Therapeutics
  • ImmunoGen
  • Immunomedics
  • Progenics Pharmaceuticals
  • Pfizer
  • Roche / Genentech
  • Sanofi
  • Seattle Genetics

第8章 聯盟、合作

  • 概要
  • 聯盟模式
  • 聯盟一覽
  • 聯盟分析

第9章 風險企業投資

  • 概要
  • 資金提供的類型
  • 投資範例
  • 資金提供分析

第10章 學術津貼

  • 概要
  • 學術津貼的清單
  • 學術津貼分析

第11章 聯合治療

  • 概要
  • 發展的過程
  • FDA的已通過核准癌症的組合劑
  • 聯合治療:FDA指南
  • 聯合治療:ADC

第12章 新的複合平台

  • 概要
  • 第1代ADC技術
  • 第2代ADC技術
  • 第3代ADC技術
  • 演進分析

第13章 非臨床資料的評估:FIH (First in Human) 給藥

  • 概要
  • 與ADC非臨床研究
  • ICH S9指南
  • IND (Investigational New Drug) 與研究設計
  • 動物模式和毒性
  • 人的最大耐受劑量 (MTD)的預測
  • 其他考察

第14章 專利分析

第15章 案例研究:ADC MANUFACTURING

第16章 市場預測、市場機會分析

  • 本章概要
  • 範圍、規定
  • 預測手法
  • 整體市場
    • 各診療科
    • 各技術供應商
    • 各連接試劑類型
    • 各酬載類型
  • 市場預測:主要藥物類別
    • ADCETRIS
    • KADCYLA
    • MYLOTARG
    • BESPONSA
    • IMMU-132
    • Rova-T
    • IMGN853
    • RG7596
    • PSMA ADC
    • BAY 94-9343
    • SAR3419
    • IMMU-130
    • AGS 16M8F / AGS 16C3F
    • CDX-011
    • SAR566658
    • ABT-414
    • SGN-CD19A
    • IMGN529
    • ASG-22ME
      • 對象患者人口
      • 銷售額預測

第17章 SWOT分析

第18章 總論

第19章 採訪記錄

第20章 附錄:圖表資料

第21章 附錄:企業、組織清單

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: RA10093

Since the first approval of MYLOTARG™ in 2000 and its subsequent withdrawal in the year 2010, the ADC market has evolved considerably. In the last seven years, the market has witnessed an increasing interest from drug developers and healthcare investors alike. Post the commercialization of ADCETRIS® in 2011 and KADCYLA® in 2013, there was a temporary, but evident, decline in the popularity of ADCs. This was attributed to the fact that no new ADC candidates were approved after 2013 and the focus had shifted to other novel therapies, such as immune checkpoint inhibitors and T-cell therapies. However, the recent approval of BESPONSA® and re-approval of MYLOTARG™ has renewed the interest of stakeholders in the domain. This growing popularity and potential of ADCs can also be correlated with an exponential increase in the number of patents that have been filed; the cumulative number has increased from 1,395 patents in 2009 to 10,208 patents in the first half of 2017.

While there are close to 200 ADCs in clinical / preclinical stages of development, the field is currently going through a gradual transition. The industry is shifting from relying on conventional technologies to newer approaches for generating ADCs. This transition has paved way for several well-funded start-ups, which offer novel conjugation approaches, more potent warheads and modified linker technologies. In addition, the ADCs are now being evaluated in combination with several other novel therapies, such as immune checkpoint inhibitors, epigenetic modulators and monoclonal antibodies.

Synopsis

The 'Antibody Drug Conjugates Market (4th Edition), 2017-2030 ' report provides a comprehensive study on the current landscape of ADCs, featuring an elaborate discussion on the future potential of this evolving market. The field has captured the interest of several drug developers, both small and large companies. While more than half of these pipeline candidates are in the discovery / preclinical stages, around 10% of candidate therapies are presently in advanced stages (phase II and above); we anticipate the market to witness continued growth in the next 5-10 years. Amongst other elements, the report features:

  • A discussion on the pipeline of ADCs along with information on the developers / technology providers, phase of development of candidate therapies, drug targets, therapeutic indications, and the types of linkers and payloads / warheads used.
  • Identification of the most commonly targeted therapeutic indications and details of the ADCs being developed against them. The study highlights the key epidemiological facts about the diseases and also lists the currently available treatment options.
  • Extensive review on the key opinion leaders (KOLs) in the field of ADCs; the report contains a detailed 2X2 analysis to assess the relative experience of certain KOLs. It also contains schematic representations of world maps highlighting the geographical locations of these eminent scientists / researchers.
  • An assessment of the various therapies that are being evaluated in combination with ADCs; the study also presents the likely evolution of these therapies across different therapeutic indications.
  • Elaborate profiles of clinical stage companies and their respective product portfolios; each profile features an overview of the company, its financial performance, product portfolio, and detailed information on advanced stage pipeline candidates (featuring a drug overview, clinical development plan and clinical trial results).
  • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, license agreements, mergers and acquisitions, manufacturing and service agreements, and other relevant agreements.
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are focused in this area. Moreover, the report features a detailed study on the various grants that have been awarded to research institutes in this field.
  • A review of the evolution of ADC conjugation technologies, highlighting the various approaches that have been adopted across different generations. This section also highlights the competition between contemporary technology platforms.
  • An overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection in ADCs. The study presents findings from various ADC studies in different animal models. The report presents an analysis of the different methods used in estimating FIH doses. In addition, it presents possible FIH starting doses and the estimated dose escalations required to reach human maximum tolerated dose (MTD).
  • A detailed analysis of the patents that have recently been filed related to ADCs. The study also highlights the emerging trends in innovation and identifies the key players involved. In addition, it presents a high-level view on the valuation of these patents.
  • A detailed case study on ADC contract manufacturers, highlighting the prevalent and emerging trends in ADC manufacturing.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2017-2030. The research, analysis and insights presented in this report include potential sales of ADCs that are currently marketed or are in the late stages of development. To account for the uncertainties associated with the development of novel ADCs and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were influenced by discussions with senior stakeholders in the industry. These include Alan Burnett (Professor, School of Medicine, James Cardiff University), Aldo Braca, (Chief Executive Officer, BSP Pharmaceuticals), Anthony DeBoer (Director, Business Development, Synaffix), Anonymous (Chief Executive Officer, Leading CMO), Christian Bailly (Head of CDMO, Pierre Fabre), Christian Rohlff, (Founder and CEO, Oxford BioTherapeutics), Anonymous (Director, Business Development, Leading CMO), John Burt (Chief Executive Officer, Abzena), Laurent Ducry (ADC R&D, Lonza), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Sasha Koniev (Chief Executive Officer, Syndivia), Stacy McDonald (Group Product Manager) and Jennifer L. Mitcham (Director, Business Development, Catalent Pharma Solutions). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • 1. Close to 200 ADCs are currently being developed across various stages of development for a diverse range of indications. Around 60% of these drugs are in the preclinical / discovery stages.
  • 2. Of the clinical stage candidates, more than 12% are being developed for breast cancer, while around 10% are being developed for the treatment of NHL. Candidates targeting AML and multiple myeloma together occupy 14% (7% each) of the clinical pipeline.
  • 3. Around 44% of the clinical ADCs are based on auristatins (29%) and maytansinoids (15%) based cytotoxic payloads. Several highly potent payloads are being evaluated in early stages of development.
  • 4. Close to 50% of the total ADC clinical trials (completed / recruiting) are evaluating ADCs in combination with other therapies. In the last two years, several novel combinations have been studied with ADCs; these include combinations with PI3K inhibitors, TYK inhibitors, BTK inhibitors, CDK inhibitors, HDAC inhibitors and EGFR inhibitors
  • 5. More than half of the ADCs in the current clinical pipeline are being developed using the technologies provided by Seattle Genetics and ImmunoGen; however, several small sized companies have emerged in last few years, offering novel technology platforms. Some of the approaches that have been adopted for the development of third generation ADC conjugation platforms include (in alphabetical order) avoiding / limiting retro-Michael drug de-conjugation (Kyowa Hakko Kirin, MedImmune, Pfizer, ProLynx, Seattle Genetics, Syndivia), cysteine re-bridging (Abzena, Igneica Biotherapeutics, University College London / ThioLogics), enzyme-assisted ligation (Catalent / Redwood, Innate Pharma, LegoChem Biosciences, NBE Therapeutics, Pfizer, Sanofi, Tubulis Technologies, ProBioGen), glycan re-modelling (Philogen, Seattle Genetics, Sanofi, Synaffix, University of Georgia, US National Cancer Institute), and ligation at Fab nucleotide-binding site (Meditope Biosciences, University of California).
  • 6. Over 10,000 patents, related to ADCs, have been filed in last decade alone. ImmmunoGen, Genentech, Seattle Genetics and Immunomedics were the first to enter this domain, and currently have the highest number of patents related to ADCs. Of these, Genentech has the maximum number of international patents (55%). Other leading players include (in decreasing order of number of patents) Roche, Novartis, AbbVie, Pfizer, Amgen, Immunomedics and University of California.
  • 7. The innovation in this domain is also being driven by academic / research institutes. In last five years, close to 80 academic grants have been awarded to various such institutes in the US alone. Majority of the grants have been awarded for research projects (29%), followed by investigator-initiated intramural research projects (22%) and exploratory / development grants (12%). Around 15% of the grants are Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants.
  • 8. Around 100 funding instances, worth USD 2.5 billion, to support research and development in ADCs have been reported in last decade. 5AM Ventures, South East Growth Fund & Management, Oxford Capital Partners, CTI Life Sciences Fund, SV Life Sciences and Alta Partners have emerged as some of the prominent investors (in terms of number of funding instances). Moreover, since 2010, more than 110 partnerships have been inked in the ADC space.
  • 9. With close to 20 drugs, that are either approved or are in late stages of clinical development (phase II and above), the ADCs therapeutics market is anticipated to grow at a CAGR to 19.4% between 2017 and 2030. The currently marketed ADCs target breast cancer and various forms of Hodgkin's lymphoma. With approval of additional ADCs, in 2030, close to 55% of the market is likely to be driven by four indications, namely breast cancer (22%), lung cancer (15%), Hodgkin's lymphoma (10%) and melanoma (8%).

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the ADCs market in the short-mid and long term.

Chapter 3 provides a general introduction to ADCs. In this section, we have discussed, in detail, the concept of ADC, its components, mechanisms of action and advantages over traditional targeted therapies. The chapter also presents a brief description of the Absorption, Distribution, Metabolism and Excretion (ADME) properties of the various ADCs in development.

Chapter 4 provides a comprehensive overview of the market landscape of ADCs under development (clinical and preclinical). This chapter includes information related to these candidates, along with their current phase of development, key target indications, developer companies and the most common types of cytotoxins and linkers used. The chapter also highlights the various ADCs that have been discontinued over the last few years.

Chapter 5 provides an extensive list of the key opinion leaders (KOLs) in the field of ADCs. It contains schematic representations of world maps highlighting the geographical locations of these eminent scientists / researchers. The chapter presents a detailed 2X2 analysis to assess the relative experience of certain KOLs based on the number of clinical studies they participated in and the highest phase of development they investigated.

Chapter 6 identifies the most commonly targeted therapeutic indications and features brief discussions on the ADCs being developed against them. It highlights the key epidemiological facts of the various disorders and lists the currently available treatment options.

Chapter 7 presents elaborate profiles of clinical stage companies and drugs; each profile features an overview of the company, its financial performance and product portfolio, including detailed information on advanced stage pipeline candidates (featuring a drug overview, mechanism of action, information on clinical trials and key clinical trial results).

Chapter 8 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also highlighted the key players, the different partnership models (such as R&D agreements, technology / product licensing, product development and commercialization agreements, mergers / acquisitions, and clinical trial collaborations) and the most common forms of deals / agreements that have been established in this domain.

Chapter 9 presents details on various investments received by companies that are focused on development of ADCs. It also includes an analysis of the funding instances that have taken place in last ten years, highlighting the growing interest of the venture capital community and other strategic investors in this market.

Chapter 10 provides a detailed analysis of the academic grants that have been awarded in this field. In addition to highlighting various key funding institutes, the chapter provides various indications and molecular targets across which, majority of the research work is currently focused.

Chapter 11 features an overview of the various therapies being evaluated in combination with ADCs. It also features a study of the likely evolution of these therapies across different therapeutic indications.

Chapter 12 features an elaborate discussion and competitive analysis of the various ADC conjugation approaches. This chapter also features an overview of the evolution of these technologies in addition to highlighting the competition between contemporary technology platforms.

Chapter 13 provides an overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection. The chapter presents insights from recently conducted studies in different animal models, analyzing the different methods used in estimating FIH doses. In addition, it presents possible FIH starting doses and the estimated dose escalations required to reach human maximum tolerated dose (MTD). The chapter highlights different types of ADC related toxicities observed in animal models, highlighting the doses at which these toxicities were observed.

Chapter 14 provides a detailed analysis of the patents that have been filed in the ADCs space. The study highlights emerging trends in the patents that have been filed and identifies the key players that are driving the innovation in this area. It also presents a high-level view on the valuation of these patents.

Chapter 15 provides details on the various players that offer contract manufacturing services for ADCs, or possess the necessary capabilities and infrastructure to manufacture such products in-house. The chapter illustrates the manufacturing capabilities of different contract manufacturers highlighting the various recent expansion plans and other agreements inked between companies.

Chapter 16 presents a comprehensive market forecast analysis, highlighting the future potential of the market till the year 2030. It includes future sales projections of ADCs that are either marketed or are in advanced stages of clinical development (phase II and preregistration). The sales potential and growth opportunity were estimated based on the target patient population, likely adoption rates, existing / future competition from other drug classes and the likely price of products. The chapter also presents a detailed market segmentation on the basis of key indications, payloads and linkers. [

Chapter 17 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the ADCs market within the biopharmaceutical industry, under a comprehensive SWOT framework.

Chapter 18 summarizes the overall report. The chapter provides a list of the key takeaways and presents our independent opinion on the ADC market, based on the research and analysis described in the previous chapters.

Chapter 19 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Alan Burnett (Professor, School of Medicine, James Cardiff University), Aldo Braca, (Chief Executive Officer, BSP Pharmaceuticals), Anthony DeBoer (Director, Business Development, Synaffix), Anonymous (Chief Executive Officer, Leading CMO), Christian Bailly (Head of CDMO, Pierre Fabre), Christian Rohlff, (Founder and CEO, Oxford BioTherapeutics), Anonymous (Director, Business Development, Leading CMO), John Burt (Chief Executive Officer, Abzena), Laurent Ducry (ADC R&D, Lonza), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Sasha Koniev (Chief Executive Officer, Syndivia), Stacy McDonald (Group Product Manager) and Jennifer L. Mitcham (Director, Business Development, Catalent Pharma Solutions).

Chapter 20 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 21 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Evolution of Cancer Treatment
  • 3.3. Cancer Treatment Methods
    • 3.3.1. Surgery
    • 3.3.2. Radiation Therapy
    • 3.3.3. Chemotherapy
    • 3.3.4. Targeted Therapies
  • 3.4. Monoclonal Antibodies to Treat Cancer
  • 3.5. Essential Components of Antibody Drug Conjugates (ADCs)
    • 3.5.1. Antibody
    • 3.5.2. Cytotoxin
    • 3.5.3. Linker
  • 3.6. Advantages of ADCs over Traditional Therapeutics
  • 3.7. ADCs, Monoclonal Antibodies and Small Molecule Drugs: Comparison of Key Properties
  • 3.8. ADME Properties of ADCs
    • 3.8.1. Absorption
    • 3.8.2. Distribution
    • 3.8.3. Metabolism and Elimination

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. ADCs: Clinical Pipeline
    • 4.2.1. ADCs Clinical Pipeline: Distribution by Phase of Development
    • 4.2.2. ADCs Clinical Pipeline: Distribution by Indication
    • 4.2.3. ADCs Clinical Pipeline: Distribution by Target
    • 4.2.4. ADCs Clinical Pipeline: Distribution by Type of Linker
    • 4.2.5. ADCs Clinical Pipeline: Distribution by Type of Warhead
    • 4.2.6. ADCs Clinical Pipeline: Distribution by Technology Providers
    • 4.2.7. ADCs Clinical Pipeline: Distribution by Targets and Indication
    • 4.2.8. ADCs Clinical Pipeline: Four-Dimensional Grid Analysis
    • 4.2.9. ADCs Clinical Pipeline: Discontinued Drugs
  • 4.3. ADCs: Preclinical Pipeline
    • 4.3.1. ADCs Preclinical Pipeline: Distribution by Key Players

5. KEY OPINION LEADERS

  • 5.1. Chapter Overview
  • 5.2. Current Research Landscape
    • 5.2.1. ADCETIRS®: Key Opinion Leaders
    • 5.2.2. KADCYLA®: Key Opinion Leaders
    • 5.2.3. MYLOTARG™: Key Opinion Leaders
    • 5.2.4. Other ADCs: Key Opinion Leaders
  • 5.3. Most Prominent Key Opinion Leaders

6. KEY THERAPEUTIC AREAS

  • 6.1. Chapter Overview
  • 6.2. Hematological Malignancies
    • 6.2.1. Leukemias and Lymphomas
      • 6.2.1.1. Leukemia: Introduction and Epidemiology
        • 6.2.1.1.1. Acute Myeloid Leukemia
        • 6.2.1.1.2. Chronic Myeloid Leukemia
        • 6.2.1.1.3. Acute Lymphocytic Leukemia
        • 6.2.1.1.4. Chronic Lymphocytic Leukemia
      • 6.2.1.2. Lymphoma: Introduction and Epidemiology
      • 6.2.1.3. Current Treatment Landscape
      • 6.2.1.4. ADCs for Leukemia / Lymphoma
    • 6.2.2. Multiple Myeloma
      • 6.2.2.1. Introduction and Epidemiology
      • 6.2.2.2. Current Treatment Landscape
      • 6.2.2.3. ADCs for Multiple Myeloma
  • 6.3. Solid Tumors
    • 6.3.1. Metastatic Melanoma
      • 6.3.1.1. Introduction and Epidemiology
      • 6.3.1.2. Current Treatment Landscape
      • 6.3.1.3. ADCs for Metastatic Melanoma
    • 6.3.2. Lung Cancer
      • 6.3.2.1. Introduction and Epidemiology
      • 6.3.2.2. Current Treatment Landscape
      • 6.3.2.3. ADCs for Lung Cancer
    • 6.3.3. Bladder Cancer
      • 6.3.3.1. Introduction and Epidemiology
      • 6.3.3.2. Current Treatment Landscape
      • 6.3.3.3. ADCs for Bladder Cancer
    • 6.3.4. Kidney Cancer
      • 6.3.4.1. Introduction and Epidemiology
      • 6.3.4.2. Current Treatment Landscape
      • 6.3.4.3. ADCs for Kidney Cancer
    • 6.3.5. Ovarian Cancer
      • 6.3.5.1. Introduction and Epidemiology
      • 6.3.5.2. Current Treatment Landscape
      • 6.3.5.3. ADCs for Ovarian Cancer
    • 6.3.6. Breast Cancer
      • 6.3.6.1. Introduction and Epidemiology
      • 6.3.6.2. Current Treatment Landscape
      • 6.3.6.3. ADCs for Breast Cancer
    • 6.3.7. Glioblastoma
      • 6.3.7.1. Introduction and Epidemiology
      • 6.3.7.2. Current Treatment Landscape
      • 6.3.7.3. ADCs for Glioblastoma
    • 6.3.8. Colorectal Cancer
      • 6.3.8.1. Introduction and Epidemiology
      • 6.3.8.2. Current Treatment Landscape
      • 6.3.8.3. ADCs for Colorectal Cancer
    • 6.3.9. Prostate Cancer
      • 6.3.9.1. Introduction and Epidemiology
      • 6.3.9.2. Current Treatment Landscape
      • 6.3.9.3. ADCs for Prostate Cancer

7. COMPANY AND DRUG PROFILES

  • 7.1. Chapter Overview
  • 7.2. AbbVie
    • 7.2.1. Company Overview
    • 7.2.2. Financial Performance
    • 7.2.3. Pipeline Overview
      • 7.2.3.1. ABT-414
        • 7.2.3.1.1 Drug Overview
        • 7.2.3.1.2. Mechanism of Action
        • 7.2.3.1.3. Clinical Development Status
        • 7.2.3.1.4. Key Clinical Trial Results
    • 7.2.4. Recent Collaborations
  • 7.3. Astellas Pharma
    • 7.3.1. Company Overview
    • 7.3.2. Financial Performance
    • 7.3.3. Pipeline Overview
      • 7.3.3.1. ASG-22ME
        • 7.3.3.1.1. Drug Overview
        • 7.3.3.1.2. Mechanism of Action
        • 7.3.3.1.3. Clinical Development Status
        • 7.3.3.1.4. Key Clinical Trial Results
      • 7.3.3.2. ASG16-M8F
        • 7.3.3.2.1. Drug Overview
        • 7.3.3.2.2. Mechanism of Action
        • 7.3.3.2.3. Clinical Development
        • 7.3.3.2.4. Key Clinical Trial Results
    • 7.3.4. Recent Collaborations
  • 7.4. Bayer HealthCare
    • 7.4.1. Company Overview
    • 7.4.2. Financial Performance
    • 7.4.3. Pipeline Overview
      • 7.4.3.1. BAY 94-9343
        • 7.4.3.1.1. Drug Overview
        • 7.4.3.1.2. Mechanism of Action
        • 7.4.3.1.3. Clinical Development Status
        • 7.4.3.1.4. Key Clinical Results
    • 7.4.4. Recent Collaborations
  • 7.5. Biotest Pharmaceuticals
    • 7.5.1. Company Overview
    • 7.5.2. Financial Performance
    • 7.5.3. Pipeline Overview
      • 7.5.3.1. BT-062
        • 7.5.3.1.1. Drug Overview
        • 7.5.3.1.2. Mechanism of Action
        • 7.5.3.1.3. Clinical Development Status
        • 7.5.3.1.4. Key Clinical Trial Results
    • 7.5.4. Recent Collaborations
  • 7.6. Celldex Therapeutics
    • 7.6.1. Company Overview
    • 7.6.2. Financial Performance
    • 7.6.3. Pipeline Overview
      • 7.6.3.1. CDX-011
        • 7.6.3.1.1. Drug Overview
        • 7.6.3.1.2. Mechanism of Action
        • 7.6.3.1.3. Clinical Development Status
        • 7.6.3.1.4. Key Clinical Trial Results
    • 7.6.4. Recent Collaborations
  • 7.7. ImmunoGen
    • 7.7.1. Company Overview
    • 7.7.2. Financial Performance
    • 7.7.3. Pipeline Overview
      • 7.7.3.1. IMGN853
        • 7.7.3.1.1. Drug Overview
        • 7.7.3.1.2. Mechanism of Action
        • 7.7.3.1.3. Clinical Development Status
        • 7.7.3.1.4. Key Clinical Trial Results
      • 7.7.3.2. IMGN529 / Debio1562
        • 7.7.3.2.1. Drug Overview
        • 7.7.3.2.2. Mechanism of Action
        • 7.7.3.2.3. Clinical Development Status
        • 7.7.3.2.4. Key Clinical Results
      • 7.7.3.3. SAR3419
        • 7.7.3.3.1. Drug Overview
        • 7.7.3.3.2. Mechanism of Action
        • 7.7.3.3.3. Clinical Development Status
        • 7.7.3.3.4. Key Clinical Trial Results
    • 7.7.4. Collaborations
  • 7.8. Immunomedics
    • 7.8.1. Company Overview
    • 7.8.2. Financial Performance
    • 7.8.3. Pipeline Overview
      • 7.8.3.1. IMMU-130
        • 7.8.3.1.1. Drug Overview
        • 7.8.3.1.2. Mechanism of Action
        • 7.8.3.1.3. Clinical Development Status
        • 7.8.3.1.4. Key Clinical Trial Results
      • 7.8.3.2. IMMU-132
        • 7.8.3.2.1. Drug Overview
        • 7.8.3.2.2. Mechanism of Action
        • 7.8.3.2.3. Clinical Development Status
        • 7.8.3.2.4. Key Clinical Trial Results
    • 7.8.4. Recent Collaborations
  • 7.9. Progenics Pharmaceuticals
    • 7.9.1. Company Overview
    • 7.9.2. Financial Performance
    • 7.9.3. Pipeline Overview
      • 7.9.3.1. PSMA ADC
        • 7.9.3.1.1. Drug Overview
        • 7.9.3.1.2. Mechanism of Action
        • 7.9.3.1.3. Clinical Development Status
        • 7.9.3.1.4. Key Clinical Trial Results
    • 7.9.4. Recent Collaborations
  • 7.10. Pfizer
    • 7.10.1. Company Overview
    • 7.10.2. Financial Performance
    • 7.10.3. Pipeline Overview
      • 7.10.3.1. BESPONSA®
        • 7.10.3.1.1. Drug Overview
        • 7.10.3.1.2. Mechanism of Action
        • 7.10.3.1.3. Approval History
        • 7.10.3.1.4. Clinical Development Status
        • 7.10.3.1.5. Key Clinical Trial Results
      • 7.10.3.2. MYLOTARG™
        • 7.10.3.2.1. Drug Overview
        • 7.10.3.2.2. Mechanism of Action
        • 7.10.3.2.3. Approval History
        • 7.10.3.2.4. Clinical Development Status
        • 7.10.3.2.5. Key Clinical Trial Results
    • 7.10.4. Recent Collaborations
  • 7.11. Roche / Genentech
    • 7.11.1. Company Overview
    • 7.11.2. Financial Performance:
    • 7.11.3. Pipeline Overview
      • 7.11.3.1. KADCYLA®
        • 7.11.3.1.1. Drug Overview
        • 7.11.3.1.2. Mechanism of Action
        • 7.11.3.1.3. Cost, Dosage and Reimbursement
        • 7.11.3.1.4. Approval History
        • 7.11.3.1.5. KADCYLA Sales, 2013-Q1 2017
        • 7.11.3.1.6. Clinical Development Status
        • 7.11.3.1.7. Key Clinical Trial Results
      • 7.11.3.2. RG-7596
        • 7.11.3.2.1. Drug Overview
        • 7.11.3.2.2. Mechanism of Action
        • 7.11.3.2.3. Clinical Development
        • 7.11.3.2.4. Key Clinical Trial Results
    • 7.11.4. Recent Collaborations
  • 7.12. Sanofi
    • 7.12.1. Company Overview
    • 7.12.2. Financial Performance-
    • 7.12.3. Pipeline Overview
      • 7.12.3.1. SAR-566658 / huDS6-DM4
        • 7.12.3.1.1. Drug Overview
        • 7.12.3.1.2. Mechanism of Action
        • 7.12.3.1.3. Clinical Development
        • 7.12.3.1.4. Key Clinical Results
    • 7.12.4. Recent Collaborations
  • 7.13. Seattle Genetics
    • 7.13.1. Company Overview
    • 7.13.2. Financial Performance
    • 7.13.3. Pipeline Overview
      • 7.13.3.1. ADCETRIS®
        • 7.13.3.1.1. Drug Overview
    • 7.13.4. Mechanism of Action
      • 7.13.4.1.1. Cost, Dosage and Reimbursement
        • 7.13.4.1.2. Approval History
        • 7.13.4.1.3. ADCETRIS® Sales, 2011-H1 2017
        • 7.13.4.1.4. Clinical Development
        • 7.13.4.1.5. Key Clinical Trial Results
      • 7.13.4.2. SGN-CD19A
        • 7.13.4.2.1. Drug Overview
        • 7.13.4.2.2. Mechanism of Action
        • 7.13.4.2.3. Clinical Development
        • 7.13.4.2.4. Key Clinical Trial Results
    • 7.13.5. Recent Collaborations

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. ADCs: List of Partnerships
  • 8.4. ADCs: Analysis of Partnerships
    • 8.4.1 Analysis by Year of Partnerships
    • 8.4.2. Analysis by Type of Partnerships
    • 8.4.3. Most Active Companies: Analysis by Number of Partnerships

9. VENTURE FUNDING

  • 9.1. Chapter Overview
  • 9.2. Types of Funding
  • 9.3. ADCs: Funding Instances
  • 9.4. ADCs: Analysis of Funding
    • 9.4.1. Analysis by Number of Funding Instances
    • 9.4.2. Analysis by Amount Invested
    • 9.4.3. Analysis by Type of Funding
    • 9.4.4. Most Active Companies: Analysis by Number of Funding Instances
    • 9.4.5. Most Active Investors: Analysis by Number of Funding Instances

10. ACADEMIC GRANTS

  • 10.1. Chapter Overview
  • 10.2. ADCs: List of Recent Academic Grants
  • 10.3. ADCs: Analysis of Grants
    • 10.3.1. Analysis by Number of Grants
    • 10.3.2. Analysis by Amount of Grant
    • 10.3.3. Analysis by Type of Grant
    • 10.3.4. Analysis by Leading Organization
    • 10.3.5. Analysis by Therapeutic Area
    • 10.3.6. Analysis by Therapeutic Target

11. COMBINATION THERAPIES

  • 11.1. Chapter Overview
  • 11.2. Combination Therapy: History of Development
  • 11.3. FDA-approved Combination Therapies in Oncology
  • 11.4. Combination Therapies: FDA Guidelines
    • 11.4.1. Combinations of Marketed Drugs
    • 11.4.2. Combinations of Marketed Drugs or Biologics with New Molecular Entities
    • 11.4.3. Combinations of New Molecular Entities
  • 11.5. Combination Therapies: ADCs
    • 11.5.1. ADCs Clinical Studies: Distribution by Therapy Type
    • 11.5.2. ADCs Combination Therapy Clinical Studies
    • 11.5.3. ADCs: Analysis of Combinations
      • 11.5.2.1. Analysis by Highest Phase of Development
      • 11.5.2.2. Analysis by Current Trial Status
      • 11.5.2.3. Analysis by Type of Combination Therapy
      • 11.5.2.4. Analysis by Indication and Combination

12. NOVEL CONJUGATION TECHNOLOGY PLATFORMS

  • 12.1. Chapter Overview
  • 12.2. First Generation ADC Technologies
  • 12.3. Second Generation ADC Technologies
    • 12.3.1. Cysteine and Selenocysteine Engineering
    • 12.3.2. Unnatural Amino Acid Engineering
    • 12.3.3. Amino-Terminal Engineered Serine
  • 12.4. Third Generation ADC Technologies
    • 12.4.1. Enzyme-Assisted Ligation Approaches
    • 12.4.2. Glycan Remodeling Approaches
    • 12.4.3. Ligation at Fab Nucleotide-Binding Site
    • 12.4.4. Cysteine Rebridging
    • 12.4.5. Avoiding or Limiting Retro-Michael Drug Deconjugation
  • 12.5. Evolutionary Analysis

13. ASSESMENT OF NON-CLINICAL DATA, FIRST IN HUMAN DOSING

  • 13.1. Chapter Overview
  • 13.2. ADCs and Non-Clinical Studies
  • 13.3. ICH S9 Guidelines
  • 13.4. Investigational New Drug (IND)-Enabling Study Designs
    • 13.4.1. Example Case: KADCYLA®
  • 13.5. Toxicities in Animal Models
  • 13.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans
  • 13.7. Other Key Considerations for Study Design

14. PATENT ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Scope and Methodology
  • 14.3. ADC Patents: Distribution by Publication Year
  • 14.4. ADC Patents: Distribution by Geographical Location
  • 14.5. ADC Patents: Distribution by CPC Classifications
  • 14.6. ADC Patents: Emerging Areas
  • 14.7. ADC Patents: Leading Players
  • 14.8. ADC Patents: Benchmarking Analysis
    • 14.8.1. Benchmarking Analysis: Patent Characteristics
    • 14.8.2. Benchmarking Analysis: Geographical Distribution
  • 14.9. ADC Patents: Emerging Players
  • 14.10. ADC Patents: Patent Valuation
  • 14.11. ADC Patents: Leading Citations

15. CASE STUDY: ADC MANUFACTURING

  • 15.1. Chapter Overview
  • 15.2. Key Steps in ADC Manufacturing
  • 15.3. Challenges Associated with ADC Manufacturing
  • 15.4. Limitations of In-House Manufacturing
  • 15.5. Growing Demand for Contract Manufacturing
  • 15.6. Emergence of Start-Ups Offering Contract Services
  • 15.7. Investments in ADC Manufacturing Capability Expansions
  • 15.8. Collaborations Established for ADC Manufacturing
  • 15.9. CMOs with Linker Manufacturing Capabilities
  • 15.10. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities
  • 15.11. CMOs with Conjugation Capabilities
  • 15.12. ADC One Stop Shops

16. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Scope and Limitations
  • 16.3. Forecast Methodology
  • 16.4. Overall ADCs Therapeutics Market
    • 16.4.1. ADCs Therapeutics Market: Distribution by Therapeutic Area
    • 16.4.2. ADCs Therapeutics Market: Distribution by Technology Providers
    • 16.4.3. ADCs Therapeutics Market: Distribution by Type of Linker
    • 16.4.4. ADCs Therapeutics Market: Distribution by Type of Payload
  • 16.5. ADCs Therapeutics Market: Individual Drug Forecasts
    • 16.5.1. ADCETRIS®
      • 16.5.1.1. Target Patient Population
      • 16.5.1.2. Sales Forecast
    • 16.5.2. KADCYLA®
      • 16.5.2.1. Target Patient Population
      • 16.5.2.2. Sales Forecast
    • 16.5.3. MYLOTARG™
      • 16.5.3.1. Target Patient Population
      • 16.5.3.2. Sales Forecast
    • 16.5.4. BESPONSA®
      • 16.5.4.1. Target Patient Population
      • 16.5.4.2. Sales Forecast
    • 16.5.5. IMMU-132
      • 16.5.5.1. Target Patient Population
      • 16.5.5.2. Sales Forecast
    • 16.5.6. Rova-T
      • 16.5.6.1. Target Patient Population
      • 16.5.6.2. Sales Forecast
    • 16.5.7. IMGN853
      • 16.5.7.1. Target Patient Population
      • 16.5.7.2. Sales Forecast
    • 16.5.8. RG7596
      • 16.5.8.1. Target Patient Population
      • 16.5.8.2. Sales Forecast
    • 16.5.9. PSMA ADC
      • 16.5.9.1. Target Patient Population
      • 16.5.9.2. Sales Forecast
    • 16.5.10. BAY 94-9343
      • 16.5.10.1. Target Patient Population
      • 16.5.10.2. Sales Forecast
    • 16.5.11. SAR3419
      • 16.5.11.1. Target Patient Population
      • 16.5.11.2. Sales Forecast
    • 16.5.12. IMMU-130
      • 16.5.12.1. Target Patient Population
      • 16.5.12.2. Sales Forecast
    • 16.5.13. AGS 16M8F / AGS 16C3F
      • 16.5.13.1. Target Patient Population
      • 16.5.13.2. Sales Forecast
    • 16.5.14. CDX-011
      • 16.5.14.1. Target Patient Population
      • 16.5.14.2. Sales Forecast
    • 16.5.15. SAR566658
      • 16.5.15.1. Target Patient Population
      • 16.5.15.2. Sales Forecast
    • 16.5.16. ABT-414
      • 16.5.16.1. Target Patient Population
      • 16.5.16.2. Sales Forecast
    • 16.5.17. SGN-CD19A
      • 16.5.17.1. Target Patient Population
      • 16.5.17.2. Sales Forecast
    • 16.5.18. IMGN529
      • 16.5.18.1. Target Patient Population
      • 16.5.18.2. Sales Forecast
    • 16.5.19. ASG-22ME
      • 16.5.19.1. Target Patient Population
      • 16.5.19.2. Sales Forecast

17. SWOT ANALYSIS

  • 17.1. Chapter Overview
  • 17.2. Strengths
  • 17.3. Weaknesses
  • 17.4. Opportunities
  • 17.5. Threats

18. CONCLUSION

  • 18.1. The Recent Approval of MYLOTARG™ and BESPONSA® has Renewed the Interest in ADCs
  • 18.2. In Addition to Established Players, Start-ups, Backed by Venture Capital Investors, are Significantly Driving Innovation in this Domain
  • 18.3. With Multiple Late-phase Candidates, the ADCs Space is Characterized by a Robust and Promising Pipeline
  • 18.4. More Potent Warheads, Novel Targets and Innovative Conjugation Platforms have Emerged as Potential Areas of Research
  • 18.5. Several Stakeholders have Entered into Strategic Alliances to Further R&D Efforts in this Domain
  • 18.6. CMOs Continue to a Play Significant Role in Driving the Industry Forward
  • 18.7. Post the Approval and Launch of Multiple Late-phase Product Candidates, the Market is Expected to Grow at a Rapid Pace

19. INTERVIEW TRANSCRIPTS

  • 19.1. Chapter Overview
  • 19.2. Alan Burnett, Professor, School of Medicine, James Cardiff University
  • 19.3. Sasha Koniev, Chief Executive Officer, Syndivia
  • 19.4. Anthony DeBoer, Director, Business Development, Synaffix
  • 19.4. Mark Wright, Site Head, Grangemouth, Piramal Healthcare
  • 19.6. Christian Bailly, Head of CDMO, Pierre Fabre
  • 19.7. Anonymous, Director, Business Development, Leading CMO
  • 19.8. John Burt, Chief Executive Officer, Abzena
  • 19.9. Christian Rohlff, Founder and CEO, Oxford BioTherapeutics
  • 19.10. Laurent Ducry, ADC R&D, Lonza
  • 19.11. Stacy McDonald, Group Product Manager and Jennifer L. Mitcham, Director, Business Development, Catalent Pharma Solutions
  • 19.12. Aldo Braca, Chief Executive Officer, BSP Pharmaceuticals
  • 19.13. Anonymous, Chief Executive Officer, Leading CMO

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

  • Figure 3.1 Cancer Treatments: Timeline
  • Figure 3.2 Cancer Treatments: Type of Surgeries
  • Figure 3.3 Cancer Treatments: Type of Radiation Therapies
  • Figure 3.3 Cancer Treatments: Type of Chemotherapies
  • Figure 3.4 Components of ADC
  • Figure 3.5 Comparative Analysis of Pharmacokinetic Properties of ADCs: Dosage, Regimen, Cmax and T1/2
  • Figure 4.1 ADCs Clinical Pipeline: Distribution by Phase of Development
  • Figure 4.2 ADCs Clinical Pipeline: Distribution by Indication
  • Figure 4.3 ADCs Clinical Pipeline: Distribution by Target
  • Figure 4.4 ADCs Clinical Pipeline: Distribution by Type of Linker
  • Figure 4.5 ADCs Clinical Pipeline: Distribution by Type of Warhead
  • Figure 4.6 ADCs Clinical Pipeline: Distribution by Technology Providers
  • Figure 4.7 ADCs Clinical Pipeline: Four-Dimensional Grid Analysis
  • Figure 4.8 ADCs Preclinical Pipeline: Distribution by Key Players
  • Figure 5.1 ADCETRIS®: Mapping Prominent Researchers
  • Figure 5.2 KADCYLA®: Mapping Prominent Researchers
  • Figure 5.3 MYLOTARG™: Mapping Prominent Researchers
  • Figure 5.4 Other ADCs: Mapping Prominent Researchers
  • Figure 5.5 ADCs: Prominent Key Opinion Leaders
  • Figure 6.1 Leukemia: Classification
  • Figure 6.2 Leukemia: Global Epidemiological Distribution
  • Figure 6.3 Lymphoma: Global Epidemiological Distribution
  • Figure 6.4 Multiple Myeloma: Global Epidemiological Distribution
  • Figure 6.5 Melanoma: Global Epidemiological Distribution
  • Figure 6.6 Lung Cancer: Classification
  • Figure 6.7 Lung Cancer: Global Epidemiological Distribution
  • Figure 6.8 Bladder Cancer: Global Epidemiological Distribution
  • Figure 6.9 Kidney Cancer: Global Epidemiological Distribution
  • Figure 6.10 Ovarian Cancer: Global Epidemiological Distribution
  • Figure 6.11 Breast Cancer: Global Epidemiological Distribution
  • Figure 6.12 Colorectal Cancer: Global Epidemiological Distribution
  • Figure 6.13 Prostate Cancer: Global Epidemiological Distribution
  • Figure 7.1 AbbVie: Annual Revenues, 2012-H1 2017 (USD Billion)
  • Figure 7.2 ABT-414: Registered Clinical Trials
  • Figure 7.3 Astellas Pharma: Annual Revenues, 2012-2017 (JPY Billion)
  • Figure 7.4 ASG-22ME: Registered Clinical Trials, 2017
  • Figure 7.5 ASG-22ME: Key Clinical Trial Results, June 2017
  • Figure 7.6 ASG 16M8F: Registered Clinical Trials, 2017
  • Figure 7.7 Bayer Healthcare: Annual Revenues, 2012-H1 2017 (EUR Billion)
  • Figure 7.8 BAY 94-9343: Registered Clinical Trials
  • Figure 7.9 Biotest Pharmaceuticals: Annual Revenues, 2012-2016 (EUR Million)
  • Figure 7.10 BT-062: Registered Clinical Trials
  • Figure 7.11 Celldex Therapeutics: Annual Revenues, 2012-H1 2017 (USD Million)
  • Figure 7.12 CDX-011: Registered Clinical Trials
  • Figure 7.13 ImmunoGen: Annual Revenues, 2012-H1 2017 (USD Million)
  • Figure 7.14 IMGN853: Registered Clinical Trials
  • Figure 7.15 IMGN853: Treatment-Related Adverse Events for Solid Tumors
  • Figure 7.16 IMGN853: Treatment-Related Adverse Events for Platinum Related Diseases
  • Figure 7.17 IMGN529: Registered Clinical Trials
  • Figure 7.18 Immunomedics: Annual Revenues, 2013-2017 (USD Million)
  • Figure 7.19 IMMU-130: Registered Clinical Trials
  • Figure 7.20 Progenics Pharmaceuticals: Annual Revenues, 2012-H1 2017 (USD Million)
  • Figure 7.21 PSMA ADC: Registered Clinical Trials
  • Figure 7.22 Pfizer: Annual Revenues, 2012-H1 2017 (USD Billion)
  • Figure 7.23 BESPONSA®: Registered Clinical Trials
  • Figure 7.24 MYLOTARG™: Mechanism of Action
  • Figure 7.25 Roche: Annual Revenues, 2012-H1 2017 (USD Billion)
  • Figure 7.26 KADCYLA®: Registered Clinical Trials
  • Figure 7.27 KADCYLA®: Annual Sales, 2013-Q1 2017 (CHF Million)
  • Figure 7.28 RG-7596: Registered Clinical Trials
  • Figure 7.29 Sanofi: Key Therapeutic Focus Areas
  • Figure 7.30 Sanofi: Annual Revenues, 2012-2016 (USD Billion)
  • Figure 7.31 SAR-566658: Registered Clinical Trials
  • Figure 7.32 Seattle Genetics: Annual Revenues, 2012-H1 2017 (EUR Millions)
  • Figure 7.33 ADCETRIS®: Registered Clinical Trials
  • Figure 7.34 ADCETRIS®: Annual Sales, 2012-H1 2017 (USD Million)
  • Figure 7.35 SGN-CD19A: Registered Clinical Trials
  • Figure 7.36 SGN-CD19A: Key Clinical Trial Results, December 2015
  • Figure 8.1 ADC Partnerships: Cumulative Year-wise Trend (2007-2017)
  • Figure 8.2 ADC Partnerships: Distribution by Most Active Players
  • Figure 8.3 ADC Partnerships: Distribution by Type of Collaboration
  • Figure 8.4 ADC Partnerships: Distribution by Year and Type of Collaboration
  • Figure 9.1 ADCs Investments: Cumulative Number of Funding Instances, Pre-2007-2017
  • Figure 9.2 ADCs Investments: Cumulative Amount Invested, Pre-2007-2017 (USD Million)
  • Figure 9.3 ADCs Investments: Distribution of Number of Funding Instance by Type, 2007-2017
  • Figure 9.4 ADCs Investments: Distribution of Funding Amount by Type, 2007-2017 (USD Million)
  • Figure 9.5 ADCs Investments: Distribution by Type of Funding and Amount Invested (USD Million)
  • Figure 9.6 ADCs Investments: Distribution by Leading Players
  • Figure 9.7 ADC Investments: Most Active Investors
  • Figure 10.1 ADCs Grants: Distribution by Number of Grants (2011-2017)
  • Figure 10.2 ADCs Grants: Year-wise Distribution by Grant Amount (USD Million)
  • Figure 10.3 ADCs Grants: Distribution by Grant Type
  • Figure 10.4 ADCs Grants: Distribution by States in the US
  • Figure 10.5 ADC Grants: Distribution by Leading Organizations
  • Figure 10.6 ADCs Grants: Distribution by Therapeutic Area
  • Figure 10.7 ADC Grants: Distribution by Therapeutic Target
  • Figure 11.1 ADCs Clinical Studies: Distribution by Type of Therapy Evaluation
  • Figure 11.2 ADCs Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
  • Figure 11.3 ADCs Combination Therapy Clinical Studies: Distribution by Trial Status
  • Figure 11.4 ADCs Combination Therapy Clinical Studies: Distribution by Trial Date and Type of Combination
  • Figure 11.5 ADCs Combination Therapy Clinical Studies: Distribution by Indications and Type of Combination
  • Figure 12.1 ADC Platforms: Technological Evolution
  • Figure 12.2 ADC Conjugation Platforms: Technology Landscape
  • Figure 13.1 First in Human Dose Calculation: Dose Escalation using BSA Conversion
  • Figure 13.2 Relationship between DLTs and ADC Warhead
  • Figure 13.3 Maximum Tolerated Dose (MTD): Relationship between Drug to Antibody Ratio and (Highest Non-Severely Toxic Dose) HNSTD
  • Figure 14.1 ADC Patents: Distribution by Type of Patent
  • Figure 14.2 ADC Patents: Distribution by Publication Year
  • Figure 14.3 ADC Patents: Year-wise Regional Distribution
  • Figure 14.4 ADC Patents: Cumulative Distribution by CPC Classification Symbol
  • Figure 14.5 ADC Patents: Emerging Areas
  • Figure 14.6 ADC Patents: Distribution by Leading Assignees
  • Figure 14.7 ADC Patents: Geographical Distribution of Leading Players
  • Figure 14.8 ADC Patents: Benchmarking by Patent Characteristics
  • Figure 14.9 ADC Patents: Benchmarking by Geographical Distribution
  • Figure 14.10 ADC Patents: Benchmarking by International Patents
  • Figure 14.11 ADC Patents: Emerging Players (2013-2017)
  • Figure 14.12 ADC Patents: Age of Patent
  • Figure 14.13 ADC Patents: Patent Valuation
  • Figure 16.1 Overall ADCs Therapeutics Market, 2017-2030: Base Scenario (USD Billion)
  • Figure 16.2 ADCs Therapeutics Market (USD Billion), 2017, 2025 and 2030 (Base Scenario): Distribution by Therapeutic Area
  • Figure 16.3 ADC Therapeutics Market (USD Billion), 2017, 2025 and 2030 (Base Scenario): Distribution by Technology Providers
  • Figure 16.4 ADCs Therapeutics Market (USD Billion), 2017, 2025 and 2030 (Base Scenario): Distribution by Type of Linker
  • Figure 16.5 ADCs Therapeutics Market (USD Billion), 2017, 2025 and 2030 (Base Scenario): Distribution by Type of Payload
  • Figure 16.6 ADCETRIS® Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.7 KADCYLA® Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.8 MYLOTARG™ Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.9 BESPONSA® Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.10 IMMU-132 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.11 Rova-T Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.12 IMGN853 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.13 RG7596 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.14 PSMA ADC Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.15 BAY 94-9343 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.16 SAR3419 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.17 IMMU-130 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.18 AGS 16M8F / AGS 16C3F Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.19 CDX-011 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.20 SAR56668 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.21 ABT-414 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.22 SGN-CD19A Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.23 IMGN529 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.24 ASG-22ME Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.1 ADCs SWOT Analysis: Overview
  • Figure 17.2 ADCs SWOT Analysis: Strengths
  • Figure 17.3 ADCs SWOT Analysis: Weaknesses
  • Figure 17.4 ADCs SWOT Analysis: Opportunities
  • Figure 17.5 ADCs SWOT Analysis: Threats
  • Figure 19.1 Overall ADCs Therapeutic Market: Conservative, Base and Optimistic Scenario, 2017, 2025 and 2030 (USD Billion)

List of Tables

  • Table 3.1 FDA Approved Antibody Based Therapeutics for Cancer
  • Table 3.2 Commonly Used Cytotoxins for ADC Therapeutics
  • Table 3.3 Occupational Exposure Limit (OEL): Bands
  • Table 3.4 Comparison of Pharmacokinetic Properties: ADCs, Small Molecules and Monoclonal Antibodies
  • Table 4.1 ADCs: Clinical Pipeline
  • Table 4.2 ADCs: Clinical Pipeline (Linker and Payloads)
  • Table 4.3 ADCs: Discontinued Drugs
  • Table 4.4 ADCs: Preclinical Pipeline
  • Table 5.1 ADCs: List of KOLs
  • Table 6.1 Comparison of Hodgkin's and Non-Hodgkin's Lymphoma
  • Table 6.2 Leukemia: List of Marketed Targeted Therapeutics
  • Table 6.3 Lymphoma: List of Marketed Targeted Therapeutics
  • Table 6.4 ADCs for Leukemia and Lymphoma
  • Table 6.5 Multiple Myeloma: List of Marketed Targeted Therapeutics
  • Table 6.6 ADCs for Multiple Myeloma
  • Table 6.7 Melanoma: List of Marketed Targeted Therapeutics
  • Table 6.8 ADCs for Metastatic Melanoma
  • Table 6.9 Lung Cancer: List of Marketed Targeted Therapeutics
  • Table 6.10 ADCs for Lung Cancer
  • Table 6.11 ADCs for Bladder Cancer
  • Table 6.12 Renal Cell Carcinoma: List of Marketed Targeted Therapeutics
  • Table 6.13 ADCs for Kidney Cancer
  • Table 6.14 ADCs for Ovarian Cancer
  • Table 6.15 Breast Cancer: List of Marketed Targeted Therapeutics
  • Table 6.16 ADCs for Breast Cancer
  • Table 6.17 ADCs for Glioblastoma
  • Table 6.18 Colorectal Cancer: List of Marketed Targeted Therapeutics
  • Table 6.19 ADCs for Colorectal Cancer
  • Table 6.20 Prostate Cancer: List of Marketed Targeted Therapeutics
  • Table 6.21 ADCs for Prostate Cancer
  • Table 7.1 AbbVie: ADCs Pipeline
  • Table 7.2 ABT-414: Registered Clinical Trials
  • Table 7.3 Astellas Pharma: ADCs Pipeline
  • Table 7.4 ASG-22ME: Registered Clinical Trials
  • Table 7.5 ASG 16M8F: Registered Clinical Trials
  • Table 7.6 Bayer Healthcare: ADCs Pipeline
  • Table 7.7 BAY 94-9343: Registered Clinical Trials
  • Table 7.8 Biotest Pharmaceuticals: ADCs Pipeline
  • Table 7.9 BT-062: Registered Clinical Trials
  • Table 7.10 Celldex Therapeutics: ADCs Pipeline
  • Table 7.11 CDX-011: Registered Clinical Trials
  • Table 7.12 ImmunoGen: ADCs Pipeline
  • Table 7.13 IMGN853: Registered Clinical Trials
  • Table 7.14 IMGN529: Registered Clinical Trials
  • Table 7.15 Immunomedics: ADCs Pipeline
  • Table 7.16 IMMU-130: Registered Clinical Trials
  • Table 7.17 IMMU-130: Registered Clinical Trials
  • Table 7.18 Progenics Pharmaceuticals: ADCs Pipeline
  • Table 7.19 PSMA ADC: Registered Clinical Trials
  • Table 7.20 Pfizer: ADCs Pipeline
  • Table 7.21 BESPONSA®: Registered Clinical Trials
  • Table 7.22 MYLOTARG™: Registered Clinical Trials
  • Table 7.23 Roche: ADCs Pipeline
  • Table 7.24 KADCYLA®: Ongoing Clinical Trials
  • Table 7.25 RG-7596: Registered Clinical Trials
  • Table 7.26 ASG-22ME: Registered Clinical Trials
  • Table 7.27 Seattle Genetics: ADCs Pipeline
  • Table 7.28 ADCETRISR®: Registered Clinical Trials
  • Table 7.29 SGN-CD19A: Registered Clinical Trials
  • Table 8.1 ADCs: List of Partnerships, 2005-2017
  • Table 9.1 ADCs: List of Funding Instances, Pre-2007-2017
  • Table 9.2 ADCs: Types of Funding Instances, Pre- 2007-2017
  • Table 10.1 ADCs: List of Academic Grants, 2011-2017
  • Table 11.1 FDA Approved Combination Therapies in Oncology, 2001-2015
  • Table 11.2 ADCs Combination Therapy Clinical Studies: Key Indications
  • Table 12.1 Second Generation ADC Technologies: Cysteine and Selenocysteine Engineering
  • Table 12.2 Second Generation ADC Technologies: Unnatural Amino Acid Engineering
  • Table 12.3 Second Generation ADC Technologies: Amino-terminal Engineered Serine
  • Table 12.4 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
  • Table 12.5 Third Generation ADC Technologies: Glycan Remodeling Approaches
  • Table 12.6 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
  • Table 12.7 Third Generation ADC Technologies: Cysteine Rebridging
  • Table 12.8 Third Generation ADC Technologies: Avoiding or Limiting Retro-Michael Drug Deconjugation
  • Table 13.1 ADCs Non-Clinical Studies: Safety Packages Required
  • Table 13.2 Single Dose Study of KADCYLA® in Cynomolgus Monkey
  • Table 13.3 ADCs: Dose Limiting Toxicities in Clinical Studies
  • Table 14.1 ADCs Patents: CPC Symbol Definitions
  • Table 14.2 ADCs Patents: Most Popular CPC Symbols
  • Table 15.1 Contract Manufacturers and Their Capabilities in ADC Manufacturing
  • Table 15.2 Contract Manufacturers for ADCs: Distribution by Geography
  • Table 15.3 Full Service Provider CMOs for ADC Manufacturing: Distribution by Geography
  • Table 16.1 ADCs Therapeutics: Expected Launch Years
  • Table 16.2 ADCETRIS®: Target Patient Population
  • Table 16.3 KADCYLA®: Target Patient Population
  • Table 16.4 MYLOTARG™: Target Patient Population
  • Table 16.5 BESPONSA®: Target Patient Population
  • Table 16.6 IMMU-132: Target Patient Population
  • Table 16.7 Rova-T: Target Patient Population
  • Table 16.8 IMGN853: Target Patient Population
  • Table 16.9 RG7596: Target Patient Population
  • Table 16.10 PSMA ADC: Target Patient Population
  • Table 16.11 BAY 94-9343: Target Patient Population
  • Table 16.12 SAR3419: Target Patient Population
  • Table 16.13 IMMU-130: Target Patient Population
  • Table 16.14 AGS 16M8F / AGS 16C3F: Target Patient Population
  • Table 16.15 CDX-011: Target Patient Population
  • Table 16.16 SAR566658: Target Patient Population
  • Table 16.17 ABT-414: Target Patient Population
  • Table 16.18 SGN-CD19A: Target Patient Population
  • Table 16.19 IMGN529: Target Patient Population
  • Table 16.20 ASG-22ME: Target Patient Population
  • Table 20.1 ADCs Clinical Pipeline: Distribution by Phases of Development
  • Table 20.2 ADCs Clinical Pipeline: Distribution by Indication
  • Table 20.3 ADCs Clinical Pipeline: Distribution by Target
  • Table 20.4 ADCs Clinical Pipeline: Distribution by Types of Linker
  • Table 20.5 ADCs Clinical Pipeline: Distribution by Types of Warhead
  • Table 20.6 ADCs Clinical Pipeline: Distribution by Technology Providers
  • Table 20.7 ADCs Clinical Pipeline: Four-Dimensional Grid Analysis
  • Table 20.8 ADCs Preclinical Pipeline: Distribution by Key Players
  • Table 20.9 AbbVie: Revenue, 2012 - H1 2017 (USD Billion)
  • Table 20.10 ABT-414: Registered Clinical Trials
  • Table 20.11 Astellas Pharma: Revenue, 2012 -2017 (JPY Billion)
  • Table 20.12 ASG-22ME: Registered Clinical Trials
  • Table 20.13 ASG 16M8F: Registered Clinical Trials
  • Table 20.14 Bayer Healthcare: Revenues, 2012 - H1 2017 (EUR Billion)
  • Table 20.15 BAY 94-9343: Registered Clinical Trials
  • Table 20.16 Biotest Pharmaceuticals: Revenue, 2012-2016 (EUR Million)
  • Table 20.17 BT-062: Registered Clinical Trials
  • Table 20.18 Celldex Therapeutics: Revenue, 2012 - H1 2017 (USD Million)
  • Table 20.19 CDX-011: Registered Clinical Trials
  • Table 20.20 ImmunoGen: Revenues, 2012 - H1 2017 (USD Million)
  • Table 20.21 IMGN853: Registered Clinical Trials
  • Table 20.22 IMGN529: Registered Clinical Trials
  • Table 20.23 SAR3419: Registered Clinical Trials
  • Table 20.24 Immunomedics: Revenues 2013-2017 (USD Million)
  • Table 20.25 IMMU-130: Registered Clinical Trials
  • Table 20.26 IMMU-132: Registered Clinical Trials
  • Table 20.27 Progenics Pharmaceuticals: Revenue, 2012 - H1 2017 (USD Million)
  • Table 20.28 PSMA ADC: Registered Clinical Trials
  • Table 20.29 Pfizer: Revenues, 2012 - H1 2017 (USD Billion)
  • Table 20.30 BESPONSA®: Registered Clinical Trials
  • Table 20.31 MYLOTARG™: Registered clinical trials, 2017
  • Table 20.32 Roche: Revenues, 2012 - H1 2017 (USD Billion)
  • Table 20.33 KADCYLA®: Registered Clinical Trials
  • Table 20.34 KADCYLA® Sales: 2013- Q1 2017 (CHF Million)
  • Table 20.35 RG-7596: Registered Clinical Trials
  • Table 20.36 Sanofi: Revenues, 2012-2016 (USD Billion)
  • Table 20.37 SAR-566658: Registered Clinical Trials
  • Table 20.38 Seattle Genetics: Revenue 2012-H1 2017 (EUR Million)
  • Table 20.39 ADCETRIS®: Registered Clinical Trials
  • Table 20.40 ADCETRIS® Sales: 2012- H1 2017 (USD Million)
  • Table 20.41 SGN-CD19A: Registered Clinical Trials
  • Table 20.42 ADCs Partnerships Cumulative Trend, 2005-2017
  • Table 20.43 ADCs Partnerships: Key Players
  • Table 20.44 ADCs Partnerships: Distribution by Types
  • Table 20.45 ADCs Partnerships: Distribution by Year Wise Trend
  • Table 20.46 ADCs Investments: Cumulative Number of Funding Instances, Pre 2007 - 2017
  • Table 20.47 ADCs Investments: Cumulative Amount Invested, 2007- 2017 (USD Million)
  • Table 20.48 ADCs Investments: Distribution of Number of Funding Instance by Type, 2007 - 2017
  • Table 20.49 ADCs Investments: Distribution of Funding Amount by Funding Type, 2007 - 2017 (USD Million)
  • Table 20.50 ADCs Investments: Distribution by Leading Players
  • Table 20.51 ADCs Investments: Distribution by Leading Investors
  • Table 20.52 Academic Grant Analysis: Distribution of Number of Grants
  • Table 20.53 Academic Grant Analysis: Distribution by Grant Type
  • Table 20.54 Academic Grant Analysis: Distribution by Leading Organizations
  • Table 20.55 Academic Grant Analysis: Cumulative Distribution by Therapeutic Area
  • Table 20.56 Academic Grant Analysis: Distribution by Therapeutic Target
  • Table 20.57 ADCs Clinical Studies: Distribution by Type of Therapy Evaluation
  • Table 20.58 ADCs Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
  • Table 20.59 ADCs Combination Therapy Clinical Studies: Distribution by Trial Status
  • Table 20.60 ADC Patents: Distribution by Type of Patent
  • Table 20.61 ADCs Patents: Distribution by Publication Year
  • Table 20.62 ADCs Patents: Year-wise Regional Distribution
  • Table 20.63 ADCs Patents: Distribution by Leading Assignees
  • Table 20.64 ADCs Patents: Benchmarking by Patent Characteristics
  • Table 20.65 ADCs Patents: Benchmarking by International Patents
  • Table 20.66 ADC Patents: Age of Patent
  • Table 20.67 ADCs Patents: Patent Valuation
  • Table 20.68 Overall ADCs Therapeutics Market, 2017-2030: Optimistic Scenario (USD Billion)
  • Table 20.69 Overall ADCs Therapeutics Market, 2017-2030: Base Scenario (USD Billion)
  • Table 20.70 Overall ADCs Therapeutics Market, 2017-2030: Conservative Scenario (USD Billion)
  • Table 20.71 Overall ADCs Therapeutics Market (USD Million), Base Scenario)
  • Table 20.72 ADCs Therapeutics Market (USD Billion), 2017 (Base Scenario): Distribution by Technology Providers
  • Table 20.73 ADCs Therapeutics Market (USD Billion), 2025 (Base Scenario): Distribution by Technology Providers
  • Table 20.74 ADCs Therapeutics Market (USD Billion), 2025 (Base Scenario): Distribution by Technology Providers
  • Table 20.75 ADCs Therapeutics Market (USD Billion), 2017 (Base Scenario): Distribution by Type of Linker
  • Table 20.76 ADCs Therapeutics Market (USD Billion), 2025 (Base Scenario): Distribution by Type of Linker
  • Table 20.77 ADCs Therapeutics Market (USD Billion), 2030 (Base Scenario): Distribution by Type of Linker
  • Table 20.78 ADCs Therapeutics Market (USD Billion), 2017 (Base Scenario): Distribution by Type of Payload
  • Table 20.79 ADCs Therapeutics Market (USD Billion), 2025 (Base Scenario): Distribution by Type of Payload
  • Table 20.80 ADCs Therapeutics Market (USD Billion), 2030 (Base Scenario): Distribution by Type of Payload
  • Table 20.81 ADCETRIS® Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.82 ADCETRIS® Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.83 ADCETRIS® Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.84 KADCYLA® Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.85 KADCYLA® Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.86 KADCYLA® Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.87 MYLOTARG™ Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.88 MYLOTARG™ Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.89 MYLOTARG™ Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.90 BESPONSA® Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.91 BESPONSA® Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.92 BESPONSA® Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.93 IMMU-132 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.94 IMMU-132 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.95 IMMU-132 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.96 Rova-T Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.97 Rova-T Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.98 Rova-T Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.99 IMGN853 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.100 IMGN853 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.101 IMGN853 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.102 RG7596 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.103 RG7596 Sales Forecast (Till 2030): Conservative Scenario (USD Million
  • Table 20.104 RG7596 Sales Forecast (Till 2030): Optimistic Scenario (USD Million
  • Table 20.105 PSMA ADC Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.106 PSMA ADC Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.107 PSMA ADC Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.108 BAY 94-9343 Sales Forecast (Till 2030): Optimistic Scenario (USD Million
  • Table 20.109 BAY 94-9343 Sales Forecast (Till 2030): Base Scenario (USD Million
  • Table 20.110 BAY 94-9343 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.110 SAR3419 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.111 SAR3419 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.112 SAR3419 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.113 IMMU-130 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.114 IMMU-130 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.115 IMMU-130 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.116 AGS 16M8F / AGS 16C3F Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.117 AGS 16M8F / AGS 16C3F Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.118 AGS 16M8F / AGS 16C3F Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.119 CDX-011 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.120 CDX-011 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.121 CDX-011 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.122 SAR56668 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.123 SAR56668 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.124 SAR56668 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.125 ABT-414 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.126 ABT-414 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.127 ABT-414 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.128 SGN-CD19A Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.129 SGN-CD19A Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.130 SGN-CD19A Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.131 IMGN529 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.132 IMGN529 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.133 IMGN529 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.134 ASG-22ME Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.135 ASG-22ME Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.136 ASG-22ME Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.137 Overall ADCs Therapeutic Market: Conservative, Base and Optimistic Scenario, 2017, 2025 and 2030 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report:

  • 1. 3P Biopharmaceuticals
  • 2. 3SBio
  • 3. 5AM Ventures
  • 4. Aarhus University Hospital
  • 5. Abbott
  • 6. AbbVie
  • 7. AbbVie Contract Manufacturing
  • 8. AbGenomics
  • 9. ABL Bio
  • 10. Abraxis BioScience
  • 11. Abzena
  • 12. Academic and Community Cancer Research United (ACCRU)
  • 13. Academisch Medisch Centrum (AMC)
  • 14. Academy of Military Medical Sciences
  • 15. ACES Pharma
  • 16. Acute Leukemia French Association (ALFA)
  • 17. ADC Biotechnology
  • 18. ADC Therapeutics
  • 19. Adimab
  • 20. Advanced Biotechnologies Venture Fund
  • 21. Advanced Proteome Therapeutics Corporation
  • 22. Advantage Capital
  • 23. Advent Venture Partners
  • 24. Affimed
  • 25. Affinity Life Sciences
  • 26. Agensys
  • 27. Aichi Cancer Center Hospital
  • 28. AIDS Malignancy Consortium (AMC)
  • 29. Ajinomoto Althea
  • 30. Alcami
  • 31. Alexandria Real Estate Equities
  • 32. Alligator Bioscience
  • 33. Allos Therapeutics
  • 34. Allozyne
  • 35. Ally Bridge Group
  • 36. Almac Group
  • 37. Alnylam Pharmaceuticals
  • 38. Alta Partners
  • 39. Alteogen
  • 40. Ambrx
  • 41. Amgen
  • 42. Amgen Ventures
  • 43. AMRI
  • 44. Angiex
  • 45. Apax Partners
  • 46. APO-T
  • 47. Apposite Capital
  • 48. Apricot Capital
  • 49. Aravis Ventures
  • 50. ARCH Venture Partners
  • 51. Array BioPharma
  • 52. Arrowpoint Partners
  • 53. Asan Medical Center
  • 54. Asana BioSciences
  • 55. Ash Stevens
  • 56. Aspyrian Therapeutics
  • 57. Astellas Pharma
  • 58. AstraZeneca
  • 59. Asymchem
  • 60. Auven Therapeutics
  • 61. Avacta
  • 62. Avicenna Oncology
  • 63. AvidBiologics
  • 64. BankInvest Group
  • 65. Barbara Ann Karmanos Cancer Institute
  • 66. Baxter BioPharma Solutions
  • 67. Bayer HealthCare
  • 68. Baylor College of Medicine
  • 69. BDC Capital
  • 70. Bear Stearns Health Innoventures
  • 71. Beatson West of Scotland Cancer Centre
  • 72. Beckman Research Institute of City of Hope
  • 73. BeiGene
  • 74. Beijing Cancer Hospital
  • 75. BerGenBio
  • 76. Bicycle Therapeutics
  • 77. BioAgilytix
  • 78. BioAtla
  • 79. Biogen
  • 80. BioGeneration Ventures
  • 81. BioMed Valley Discoveries
  • 82. BioOutsource
  • 83. Bio-Synthesis
  • 84. BioTechnique
  • 85. Biotecnol
  • 86. Biotest
  • 87. BlinkBio
  • 88. Boehringer Ingelheim
  • 89. Boehringer Ingelheim Venture Fund
  • 90. BOM Capital
  • 91. Bregua Corporation
  • 92. Brigham and Women's Hospital
  • 93. Bristol-Myers Squibb (BMS)
  • 94. Brown University
  • 95. BSP Pharmaceuticals
  • 96. BZL Biologics
  • 97. California Institute for Regenerative Medicine (CIRM)
  • 98. Cambrex
  • 99. Cancer Research UK Centre for Drug Development
  • 100. Cancer Treatment Centers of America
  • 101. Cantonal Hospital St. Gallen
  • 102. CARBOGEN AMCIS
  • 103. CARB-X
  • 104. Carnegie Kapitalforvaltning
  • 105. Cascade Investment Group
  • 106. Cascadian Therapeutics
  • 107. Casdin Capital
  • 108. Catalent
  • 109. Catalent Biologics
  • 110. Catapult Ventures
  • 111. CEL Healthcare Fund
  • 112. Celgene
  • 113. Celldex Therapeutics
  • 114. Cellectar Biosciences
  • 115. Cellerant Therapeutics
  • 116. Centocor Ortho Biotech Services
  • 117. Centre Hospitalier Lyon Sud
  • 118. Centre Oscar Lambret
  • 119. Centrose
  • 120. Cerbios-Pharma
  • 121. ChemCon
  • 122. ChemPartner
  • 123. Children's Hospital Los Angeles (CHLA)
  • 124. Children's Hospital of Philadelphia (CHOP)
  • 125. Children's Mercy Hospital
  • 126. Children's Oncology Group (COG)
  • 127. Chinese Academy of Medical Sciences
  • 128. Chiron Pharmaceuticals
  • 129. CHU de Limoges
  • 130. Chugai Pharmaceuticals
  • 131. Churchill Hospital
  • 132. CMC Biologics
  • 133. COARE Biotechnology
  • 134. Columbia University
  • 135. Comprehensive Cancer Center City of Hope
  • 136. Compugen
  • 137. Concortis Biotherapeutics
  • 138. Cormorant Asset Management
  • 139. Cornell University
  • 140. Creative Biolabs
  • 141. Credit Suisse First Boston Next Fund
  • 142. Crescendo Biologics
  • 143. Crocker Ventures
  • 144. CTI Life Sciences Fund
  • 145. Cytogen
  • 146. CytomX Therapeutics
  • 147. Cytovance Biologics
  • 148. Daiichi Sankyo
  • 149. Dalton Pharma Services
  • 150. Dana-Farber Cancer Institute
  • 151. Dansk Erhvervsinvestering
  • 152. Debiopharm
  • 153. Deerfield Management
  • 154. Division of Rheumatology, Michigan Medicine
  • 155. Dophen Biomed
  • 156. Dow Employees' Pension Plan
  • 157. Dow Venture Capital
  • 158. Duke University
  • 159. Duquesne Capital Management
  • 160. ECOG-ACRIN Cancer Research Group
  • 161. EirGenix
  • 162. Eisai
  • 163. Elder Pharmaceuticals
  • 164. Eleven Biotherapeutics
  • 165. Eli Lilly
  • 166. Endo Pharmaceuticals
  • 167. Esperance Pharmaceuticals
  • 168. ETH Zurich
  • 169. Eucodis Bioscience
  • 170. Evonik
  • 171. Expansion Venture Capital
  • 172. Extend Biopharma
  • 173. Fabrus
  • 174. Ferring Pharmaceuticals
  • 175. Ferro Pfanstiehl Laboratories
  • 176. Fidelity Management & Research Company
  • 177. Fonds de solidarité FTQ
  • 178. Formation Biologics
  • 179. Formosa Laboratories
  • 180. For-Robin
  • 181. Fortis Therapeutics
  • 182. Fosun Pharma
  • 183. Fox Chase Cancer Center
  • 184. Fred Alger Management
  • 185. Fred Hutchinson Cancer Research Center
  • 186. Freeman Hospital
  • 187. FUJIFILM Diosynth Biotechnologies
  • 188. Genentech
  • 189. Genmab
  • 190. Genzyme
  • 191. German Hodgkin Study Group
  • 192. Gilead Sciences
  • 193. GlaxoSmithKline (GSK)
  • 194. Global Bio-Chem
  • 195. Glykos
  • 196. Glynn Capital
  • 197. Glythera
  • 198. Goodwin Biotechnology
  • 199. GTC Biotherapeutics
  • 200. Guardant Health
  • 201. Guy's and St. Thomas' NHS Foundation Trust
  • 202. H. Lee Moffitt Cancer Center & Research Institute
  • 203. Halozyme
  • 204. Hambrecht & Quist Capital Management
  • 205. Hangzhou DAC Biotech
  • 206. Hartmann Oncology Radiotherapy Group
  • 207. HBM Healthcare Investments
  • 208. HBM Partners
  • 209. HealthCap
  • 210. Heidelberg Pharma
  • 211. Heraeus Precious Metals
  • 212. Hercules Capital
  • 213. HNI Corporation
  • 214. Hôpital Necker-Enfants Malades
  • 215. HOPU Investment Management
  • 216. Hospital Clinic of Barcelona
  • 217. Hospital General de Valencia
  • 218. Hospital La Fe
  • 219. Hospital St. Louis
  • 220. Hospital Universitario de Salamanca
  • 221. Houston Methodist Cancer Center
  • 222. Houston Methodist Hospital
  • 223. Humanwell Healthcare
  • 224. iBIOSOURCE
  • 225. IDT Australia
  • 226. IDT Biologika
  • 227. Igenica Biotherapeutics
  • 228. ImClone Systems
  • 229. Immatics
  • 230. ImmunoGen
  • 231. Immunomedics
  • 232. INC Research
  • 233. Index Ventures
  • 234. Indiana University School of Medicine
  • 235. Indiana University Simon Cancer Center
  • 236. Innate Pharma
  • 237. Innovate UK
  • 238. Innovis Investments
  • 239. Institut Bergonié
  • 240. Institut Curie - Hôpital René Hugenin
  • 241. Institut de Cancérologie de Lorraine (ICL)
  • 242. Institut Jules Bordet
  • 243. International Biotechnology Trust
  • 244. International College of Manitoba (ICM)
  • 245. Invenra
  • 246. IONTAS
  • 247. IRCCS AOU San Martino
  • 248. Iroquois Capital Group
  • 249. Istituto di Ematologia di Bologna
  • 250. IU Health Goshen Center for Cancer Care
  • 251. JAFCO
  • 252. Janssen Biotech
  • 253. Jennison Associates
  • 254. Johns Hopkins University
  • 255. Johnson & Johnson
  • 256. Jonsson Comprehensive Cancer Center
  • 257. Kairos Therapeutics
  • 258. Kaplan Medical Center
  • 259. Karmanos Cancer Institute
  • 260. Karolinska University Hospital
  • 261. Kemwell Biopharma
  • 262. Kolltan Pharmaceuticals
  • 263. Korea Cancer Center Hospital
  • 264. Kumamoto University Hospital
  • 265. Kyowa Hakko Kirin
  • 266. Lead Discovery Center
  • 267. LegoChem Biosciences
  • 268. Lehigh University
  • 269. Leica Biosystems
  • 270. Ligand Pharmaceuticals
  • 271. Lilly Ventures
  • 272. LinXis
  • 273. LODH Private Equity
  • 274. Lombard Odier
  • 275. Lonza
  • 276. Loyola University
  • 277. Lumira Capital
  • 278. Lymphoma Study Association (LYSA)
  • 279. MAB Discovery
  • 280. MabPlex
  • 281. MabSpace Biosciences
  • 282. MabVax Therapeutics
  • 283. MacroGenics
  • 284. Masonic Cancer Center
  • 285. Massachusetts General Hospital
  • 286. Massey Cancer Center
  • 287. Maverick Capital
  • 288. Max Planck Innovation
  • 289. Mayo Clinic
  • 290. MD Anderson Cancer Center
  • 291. Medarex
  • 292. MediaPharma
  • 293. Medical College of Wisconsin
  • 294. MedImmune
  • 295. Meditope Biosciences
  • 296. Medivation
  • 297. MedStar Washington Hospital Center
  • 298. Memorial Sloan Kettering Cancer Center
  • 299. Menarini Group
  • 300. Merck Serono
  • 301. Merrimack Pharmaceuticals
  • 302. Mersana Therapeutics
  • 303. Millennium Pharmaceuticals
  • 304. MImAbs
  • 305. Minomic
  • 306. Mitsubishi Tanabe Pharma
  • 307. Modal Capital Partners
  • 308. Morphotek
  • 309. MPM Capital
  • 310. MS Seed Capital
  • 311. MS Ventures
  • 312. MultiCell Immunotherapeutics
  • 313. Nantes University Hospital
  • 314. Natco Pharma
  • 315. National Cancer Center of Korea
  • 316. National Cancer Institute
  • 317. National Research Council of Canada
  • 318. NBE Therapeutics
  • 319. Nerviano Medical Sciences
  • 320. New Enterprise Associates
  • 321. New York Medical College
  • 322. Nextech Venture
  • 323. Noonday Asset Management
  • 324. Nordic Nanovector
  • 325. Norfolk and Norwich University Hospital
  • 326. Northeast Securities Prosperity Healthcare Fund
  • 327. Northwestern University
  • 328. Novartis
  • 329. Novartis Venture Fund
  • 330. Novasep
  • 331. Novella Clinical
  • 332. Novimmune
  • 333. NSABP Foundation
  • 334. OBI Pharma
  • 335. OGD2 Pharma
  • 336. Ohio State University
  • 337. Oncology Institute of Southern Switzerland
  • 338. Oncotec Pharma Produktion
  • 339. Onyx Pharmaceuticals
  • 340. OPKO Health
  • 341. OrbiMed Advisors
  • 342. OrbiMed Associates
  • 343. Oregon Health and Science University
  • 344. Orphan Medical
  • 345. Osage University Partners
  • 346. Oslo University Hospital
  • 347. OVP Venture Partners
  • 348. Oxford BioTherapeutics
  • 349. Oxford Capital Partners
  • 350. Oxford Finance
  • 351. Oxis Biotech
  • 352. Pacific GMP
  • 353. Particle Sciences
  • 354. Patheon
  • 355. Perceptive Advisors
  • 356. PETHEMA Foundation
  • 357. Pfizer
  • 358. Pfizer Venture Investments
  • 359. Pharmacyclics
  • 360. PharmaMar
  • 361. Philochem
  • 362. Philogen
  • 363. Pierre Fabre
  • 364. Piramal Pharma Solutions
  • 365. Policlinico S. Orsola-Malpighi
  • 366. PolyTherics
  • 367. PrECOG
  • 368. Presidio Partners
  • 369. Princess Margaret Hospital
  • 370. ProBioGen
  • 371. Progenics Pharmaceuticals
  • 372. ProJect Pharmaceutics
  • 373. ProLynx
  • 374. PSI Company
  • 375. Purdue University
  • 376. QPS Holdings
  • 377. Quanta BioDesign
  • 378. Queen Elizabeth Hospital
  • 379. Ramot
  • 380. Recepta Biopharma
  • 381. Redmile Group
  • 382. Redwood Bioscience
  • 383. Redwood Pharma
  • 384. Regeneron Pharmaceuticals
  • 385. Regional Center for the Fight Against Cancer
  • 386. RemeGen
  • 387. ReqMed Company
  • 388. Research Corporation Technologies
  • 389. Roche
  • 390. Roche Venture Fund
  • 391. Rock Springs Capital Management
  • 392. Roswell Park Cancer Institute
  • 393. Royal Hospital for Children Glasgow
  • 394. Royal Liverpool Hospital
  • 395. Samsung Medical Center
  • 396. Sandoz
  • 397. Sanofi-Aventis
  • 398. Sapienza University of Rome
  • 399. Sapporo Medical University
  • 400. Sarah Cannon Research Institute
  • 401. Scale Venture Partners
  • 402. Schering-Plough
  • 403. SCIEX
  • 404. Scottish Widows Investment Partnership
  • 405. SCRI Innovations
  • 406. SEASUN BIOMATERIALS
  • 407. Seattle Cancer Care Alliance
  • 408. Seattle Genetics
  • 409. Seoul National University Hospital
  • 410. Serina Therapeutics
  • 411. Severance Hospital
  • 412. Shanghai Fosun Pharmaceutical
  • 413. Shanghai Rui Jin Hospital
  • 414. Shenogen
  • 415. Sigma-Aldrich
  • 416. Silicon Valley Bank
  • 417. Sinopharm Capital
  • 418. Skyline Ventures
  • 419. Societa Italiana Corticosteroidi
  • 420. Sofinnova Ventures
  • 421. Sorenson Development
  • 422. Sorrento Therapeutics
  • 423. SOTIO
  • 424. South East Growth Fund & Management
  • 425. Southampton General Hospital
  • 426. Southwest Oncology Group
  • 427. Spectrum Pharmaceuticals
  • 428. Spirogen
  • 429. SR One
  • 430. St James University Hospital
  • 431. St. Catherine of Siena Medical Center
  • 432. St. Joseph's Health Care
  • 433. St. Jude Children's Research Hospital
  • 434. Stanford University
  • 435. State University of New York
  • 436. Stemcentrx
  • 437. SUEZ Ventures
  • 438. Sutro Biopharma
  • 439. SV Life Sciences
  • 440. Symbiosis Pharmaceutical Services
  • 441. Symphogen
  • 442. Synaffix
  • 443. Syndivia
  • 444. Syngene
  • 445. Syntarga
  • 446. Synthon
  • 447. Synthon Biopharmaceuticals
  • 448. Synthorx
  • 449. Tagworks Pharmaceuticals
  • 450. Takeda Oncology
  • 451. Takeda Pharmaceutical
  • 452. Tavistock Life Sciences
  • 453. Tekla Healthcare Investors
  • 454. Tekla Life Science Investors
  • 455. The Chemistry Research Solution
  • 456. The Christie NHS Foundation Hospital
  • 457. The Cleveland Clinic
  • 458. The Column Group
  • 459. The Royal Marsden NHS Foundation Trust
  • 460. The Scripps Research Institute
  • 461. The Scripps Research Institute
  • 462. The Wild Family Office
  • 463. Themelios Ventures Partners
  • 464. Theranyx
  • 465. Thiel Capital
  • 466. ThioLogics
  • 467. Third Rock Ventures
  • 468. TPG-Axon Capital
  • 469. Triphase Accelerator
  • 470. Tube Pharmaceuticals
  • 471. Tubulis Technologies
  • 472. Tulane University
  • 473. Twilight Venture Partners
  • 474. UNC Lineberger Comprehensive Cancer Center
  • 475. Unilever Technology Ventures
  • 476. Union Carbide Employees' Pension Plan
  • 477. United Therapeutics
  • 478. Universitair Medisch Centrum
  • 479. Universitair Ziekenhuizen Leuven
  • 480. University Hospital Bern
  • 481. University Hospital Dresden
  • 482. University Hospital of Udine
  • 483. University Hospital of Wales
  • 484. University Hospital Ramon y Cajal
  • 485. University Hospitals Seidman Cancer Center
  • 486. University of Alabama
  • 487. University of Arizona
  • 488. University of California
  • 489. University of Cologne
  • 490. University of Copenhagen
  • 491. University of Georgia
  • 492. University of Kansas Medical Center Research Institute
  • 493. University of Miami
  • 494. University of Minnesota
  • 495. University of Munich
  • 496. University of New Mexico Cancer Center
  • 497. University of Nottingham
  • 498. University of Oklahoma Stephenson Cancer Center
  • 499. University of Pennsylvania Abramson Cancer Center (ACC)
  • 500. University of Pittsburgh
  • 501. University of Rochester Medical Center
  • 502. University of Texas Health Science Center
  • 503. University of Ulm
  • 504. University of Washington Cancer Consortium
  • 505. University of Western Ontario
  • 506. US Oncology Research
  • 507. UT Southwestern Medical Center
  • 508. Valeant Pharmaceuticals
  • 509. Vanderbilt-Ingram Cancer Center
  • 510. Venrock Healthcare Capital Partners
  • 511. Ventana Medical Systems
  • 512. Venture Associates
  • 513. Venture West
  • 514. Ventures West
  • 515. Versailles Hospital
  • 516. Versant Ventures
  • 517. Vertex Ventures
  • 518. Victor Hugo Surgical Clinic
  • 519. Virginia Cancer Specialists
  • 520. Visterra
  • 521. VivaMab
  • 522. Vivo Capital
  • 523. VLG Investments
  • 524. VU University Medical Center Amsterdam
  • 525. Vulcan Capital
  • 526. Wake Forest University Health Sciences
  • 527. Washington University School of Medicine
  • 528. Waters Corporation
  • 529. Watson Pharmaceuticals
  • 530. Weill Medical College of Cornell University
  • 531. Wellington Management Company
  • 532. Western Regional Medical Center
  • 533. Wharton Biotechnology Partners
  • 534. WILEX
  • 535. Wilmot Cancer Institute
  • 536. Wntrix
  • 537. WT Investment Advisors Fund
  • 538. WuXi AppTec
  • 539. Wyeth
  • 540. Xencor
  • 541. Xintela
  • 542. Yale University
  • 543. Yuhan Corporation
  • 544. Zhejiang Medicine
  • 545. Ziff Asset Management
  • 546. Zymeworks
  • 547. ZymoGenetics
Back to Top